BridgeBio is a San Francisco-based biotechnology researching and producing genetically-targeted therapeutics.

BridgeBio Pharma Inc is involved in identifying medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio builds out subsidiary companies around different inherited genetic diseases. The company seeks to translate scientific discoveries from universities, academic medical centers, and pharmaceutical research groups into genetically-targeted therapeutics to address the fundamental causes of diseases. The companies portfolio assets span therapeutic areas, including:

  • Genetic dermatology
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Renal disease
  • Ophthalmology

Some of the specific indications BridgeBio targets include transthyretin amyloidosis (ATTR-CM and ATTR-PN), pantothenate kinase-associated neurodegeneration, Gorlin syndrome and frequent basal cell carcinomas, dystrophic epidermolysis bullosa, Darier and Hailey-Hailey diseases, Netherton syndrome, venous malformations, Canavan disease, Leber's hereditary optic neuropathy, molybdenum cofactor deficiency Type A, achondroplasia, and FGFR, SHP-2, and K-RAS-drive cancers.


BridgeBio's partners include Leo Pharma, Leidos, Novartis, Cincinnati Children's, Boston Children's Hospital, Takeda, Infinity Pharmaceuticals, NeuroVive Pharmaceutical, St. Jude Children's Research Center, The University of Texas MD Anderson Cancer Center, Spark at Stanford, and University of California San Francisco.


October 27, 2020
BridgeBio Pharma and affiliate Phoenix Tissue Repair announce first patient dosing in Phase 2 trial of protein replacement therapy for the treatment of recessive dystrophic epidermolysis bullosa.
October 5, 2020
BridgeBio Pharma and Eidos Therapeutics announce merger agreement
September 29, 2020
BridgeBio Pharma and affiliate Origin Biosciences announces FDA acceptance of its new drug application for fosdenopterin for the treatment of MoCD Type A.
March 4, 2020
BridgeBio Pharma prices upsized offering of $475 million convertible senior notes.
March 4, 2020
BridgeBio raises a $475,000,000 venture round.
June 27, 2019
BridgeBio takes crown for biggest biotechnology IPO of 2019, pushing their share price from $14 to $16 per share up to $17 per share and raising around $348.5 million on its Nasdaq debut.
January 23, 2019
BridgeBio Pharma announced the close of a new financing round of $299.2 million.
January 23, 2019
BridgeBio raises a $299,200,000 series D round from Sequoia Capital, Viking Global Investors, Perceptive Advisors, Cormorant Capital, AIG Investments and Aisling Capital.
September 13, 2017
BridgeBio Pharma raised $135 million series C.
September 13, 2017
BridgeBio raises a $135,000,000 series C round from Viking Global Investors, Perceptive Advisors, Cormorant Capital, AIG Investments and Aisling Capital.
Page 1 of 2

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
BridgeBio Pharma funding round, January 2019
January 2019
7 Results
Results per page:
Page 1 of 1



Further reading


Documentaries, videos and podcasts





Lydia Ramsey Pflanzer
March 2, 2021
Business Insider
These are Insider's biggest healthcare stories for March 2.
Allison DeAngelis
March 1, 2021
Business Insider
BridgeBio just received FDA approval for its first drug for an ultra-rare disease. It's the first proof-point for a company that drew skepticism.
Halper Sadeh LLP
December 19, 2020
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BioTelemetry, Inc. (NASDAQ: BEAT)...
Monteverde & Associates PC
December 16, 2020
/PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State...
Nick Paul
December 7, 2020
Maze Therapeutics has partnered to create two startups focused on cardiovascular and ophthalmic diseases. The startups will benefit from Maze's human genetics and functional genomics platform as well as the capabilities of either Alloy Therapeutics or BridgeBio Pharma.
Halper Sadeh LLP
December 4, 2020
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Slack Technologies, Inc. (NYSE: WORK) concerning potential...
December 1, 2020
LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Company's Clinical Trial Application (CTA) to conduct the Phase 2a trial of infigratinib in patients with locally advanced or metastatic gastr
November 13, 2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes. BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Center's Therapeutics Discovery divis
June 11, 2020
BridgeBio Pharma, Inc. affiliate ML Bio Solutions announced that the first subject has been dosed in the Phase 1 clinical trial of BBP-418, an orally-administered small molecule therapy being evaluated for the treatment of limb girdle muscular dystrophy type 2i.
Amirah Al Idrus
June 10, 2020
Five years ago, Neil Kumar, Ph.D., quit his job at Third Rock Ventures to start a new kind of biotech company. The idea was "Moneyball" for biotech--to pick up potential rare disease treatments languishing in academia and to develop enough of them in parallel that the rare focus wouldn't scare off investors.
May 11, 2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED's plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of disproportionate short stature. Data were accepted for presentation at the Endocrine Society's Annual Meeting ("ENDO 2020"), which was cancelled due to COVID-19, and the studies


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.